EU Contribution to the African Vaccine Manufacturing Accelerator (AVMA)

The European Union and its Member States have announced a contribution of over 750 million euros to the African Vaccine Manufacturing Accelerator (AVMA). This initiative will support the growth of vaccine manufacturing in Africa and contribute to the African Union’s ambition to produce the majority of vaccines for the African market.

The AVMA will contribute to the existing Team Europe initiative on manufacturing and access to vaccines, medicines, and health technologies in Africa (Manufacturing and Access to Vaccines, Medicines and Health Technologies – MAV+). MAV+ offers a comprehensive approach to reduce barriers on both the demand and supply sides, with the goal of creating an environment that supports local production in Africa. To achieve development goals and geopolitical priorities shared by the EU and the African Union, it is essential to support access to essential health products and technologies.

This initiative can stimulate economic growth and the creation of decent jobs, facilitate trade, diversify global value chains, promote private sector engagement, and strengthen health, scientific, and diplomatic ties with partner countries, while promoting universal health coverage and human development and public health goals.

On the supply side, together with the European Investment Bank (EIB) and development banks, the Team Europe Initiatives (TEI) incentivize and de-risk investments in local pharmaceutical and biotechnology companies. On the demand side, the TEI collaborates with African leaders and partners to address the fragmentation of local markets, help consolidate demand, facilitate market integration, and promote the use of local products.

Regarding the creation of a favorable environment, the initiative will address the threat of substandard and counterfeit products and increase confidence in local products by strengthening regulatory frameworks. The initiative also supports technology transfer, for example through multilateral initiatives, particularly the WHO’s mRNA technology transfer hub and their manufacturers.

These three key dimensions revolve around six work streams:

  • industrial development, supply chains, and private sector
  • market shaping, demand, and trade facilitation
  • regulatory strengthening
  • technology transfer and intellectual property management
  • access to finance
  • research and development (R&D), higher education, and skills


Related news

27 June 2024
24 June 2024
New EU-Kenya Economic Partnership Agreement
08 May 2024
India: the busy trade agenda in Europe
foto fabio marazzi
03 May 2024
Fabio Marazzi is the new Of Counsel at Lexacta Global Legal Advice.
29 April 2024
U.S.A. Federal Trade Commission: Noncompete Rule
Return to News